Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer

IntroductionProgrammed cell death through apoptosis plays an essential role in the hormone-regulated physiological turnover of mammary tissue. Failure of this active gene-dependent process is central both to the development of breast cancer and to the appearance of the therapy-resistant cancer cells that produce clinical relapse. Functional expression cloning in two independent laboratories has identified Finkel–Biskis–Reilly murine sarcoma virus-associated ubiquitously expressed gene (Fau) as a novel apoptosis regulator and candidate tumour suppressor. Fau modifies apoptosis-controller Bcl-G, which is also a key target for candidate oncoprotein maternal embryonic leucine zipper kinase (MELK).MethodsWe have used RNA interference to downregulate Fau and Bcl-G expression, both simultaneously and independently, in breast cancer cells in vitro to determine the importance of their roles in apoptosis. Expression of Fau, Bcl-G and MELK was measured by quantitative RT-PCR in breast cancer tissue and in matched breast epithelial tissue from the same patients. Expression data of these genes obtained using microarrays from a separate group of patients were related to patient survival in Kaplan–Meier analyses.ResultssiRNA-mediated downregulation of either Fau or Bcl-G expression inhibited apoptosis, and the inhibition produced by combining the two siRNAs was consistent with control of Bcl-G by Fau. Fau expression is significantly reduced in breast cancer tissue and this reduction is associated with poor patient survival, as predicted for a candidate breast cancer tumour suppressor. In addition, MELK expression is increased in breast cancer tissue and this increase is also associated with poor patient survival, as predicted for a candidate oncogene. Bcl-G expression is reduced in breast cancer tissue but decreased Bcl-G expression showed no correlation with survival, indicating that the most important factors controlling Bcl-G activity are post-translational modification (by Fau and MELK) rather than the rate of transcription of Bcl-G itself.ConclusionsThe combination of in vitro functional studies with the analysis of gene expression in clinical breast cancer samples indicates that three functionally interconnected genes, Fau, Bcl-G and MELK, are crucially important in breast cancer and identifies them as attractive targets for improvements in breast cancer risk prediction, prognosis and therapy.

[1]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[2]  Morihiko Nakamura,et al.  Characterization of ubiquitin-like polypeptide acceptor protein, a novel pro-apoptotic member of the Bcl2 family. , 2003, European journal of biochemistry.

[3]  M. Mourtada-Maarabouni,et al.  Regulation of apoptosis by fau revealed by functional expression cloning and antisense expression , 2004, Oncogene.

[4]  David P. Davis,et al.  Maternal embryonic leucine zipper kinase/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. , 2005, Cancer research.

[5]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[6]  J. Ting,et al.  MEK Inhibition Enhances Paclitaxel-induced Tumor Apoptosis* , 2000, The Journal of Biological Chemistry.

[7]  T. Rossman,et al.  Expression cloning for arsenite-resistance resulted in isolation of tumor-suppressor fau cDNA: possible involvement of the ubiquitin system in arsenic carcinogenesis. , 1999, Carcinogenesis.

[8]  A. Wärri,et al.  Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. , 1993, Journal of the National Cancer Institute.

[9]  R. Schiff,et al.  Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. , 2006, Endocrine-related cancer.

[10]  A. Godzik,et al.  Bcl-G, a Novel Pro-apoptotic Member of the Bcl-2 Family* , 2001, The Journal of Biological Chemistry.

[11]  M. Mourtada-Maarabouni,et al.  Functional expression cloning reveals proapoptotic role for protein phosphatase 4 , 2003, Cell Death and Differentiation.

[12]  M. Mourtada-Maarabouni,et al.  GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer , 2009, Oncogene.

[13]  T L Chenevert,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Cooper,et al.  LUCA-15-encoded sequence variants regulate CD95-mediated apoptosis , 2000, Oncogene.

[15]  W. Rutter,et al.  Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. , 1979, Biochemistry.

[16]  K. Kas,et al.  fau cDNA encodes a ubiquitin-like-S30 fusion protein and is expressed as an antisense sequence in the Finkel-Biskis-Reilly murine sarcoma virus. , 1993, Oncogene.

[17]  J. Sasse,et al.  RNA isolation from cartilage using density gradient centrifugation in cesium trifluoroacetate: an RNA preparation technique effective in the presence of high proteoglycan content. , 1992, Analytical biochemistry.

[18]  R. Nahta,et al.  Trastuzumab: triumphs and tribulations , 2007, Oncogene.

[19]  I. Ellis,et al.  A gene-expression signature to predict survival in breast cancer across independent data sets , 2007, Oncogene.

[20]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[21]  J. Hickman,et al.  Developmental regulation of Bcl-2 family protein expression in the involuting mammary gland. , 1999, Journal of cell science.

[22]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[23]  Yusuke Nakamura,et al.  Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family , 2007, Breast Cancer Research.

[24]  S. Polak‐Charcon,et al.  DAP kinase links the control of apoptosis to metastasis , 1997, Nature.

[25]  S. Cory,et al.  The Bcl-2 apoptotic switch in cancer development and therapy , 2007, Oncogene.

[26]  R. Wilkins Polygenes, risk prediction, and targeted prevention of breast cancer. , 2008, The New England journal of medicine.

[27]  M. Mourtada-Maarabouni,et al.  Growth arrest in human T-cells is controlled by the non-coding RNA growth-arrest-specific transcript 5 (GAS5) , 2008, Journal of Cell Science.

[28]  R. Figlin,et al.  Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Keith Baggerly,et al.  Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression , 2004, Breast Cancer Research.

[30]  Suzanne Cory,et al.  The Bcl-2 family: roles in cell survival and oncogenesis , 2003, Oncogene.

[31]  Daniela Hoeller,et al.  Ubiquitin and ubiquitin-like proteins in cancer pathogenesis , 2006, Nature Reviews Cancer.

[32]  Gwyn T. Williams Programmed cell death: Apoptosis and oncogenesis , 1991, Cell.